

Bangladesh

Support for Vaccine: Measles and Rubella

This Decision Letter sets out the Programme Terms of a Programme

1. **Country:** Bangladesh
2. **Vaccine grant number:** BGD-MR-R-1&2-FER
3. **Date of Decision Letter:** 25 November 2021
4. **Date of the Partnership Framework Agreement:** 24 June 2013
5. **Programme title:** New Vaccine Support (NVS), Measles and Rubella, 2-dose Routine (Fragility, emergencies and refugees policy)
6. **Vaccine type:** Measles and Rubella
7. **Requested product presentation and formulation of vaccine:**
MR, 10 doses/vial, lyophilised
8. **Programme duration:¹** 2018-2022
9. **Programme Budget (indicative):²** (subject to the terms of the Partnership Framework Agreement, if applicable)

	2018-2020	2021	2022	2023	2024	2025	Total ³
Programme Budget(US\$)	646,929	288,106	273,346	-	-	-	1,208,381
10. **Vaccine introduction grant:**
Not applicable
11. **Product switch grant:**
Not applicable

¹This is the entire duration of the programme.

²This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

³This is the amount that Gavi has approved.

12. Indicative annual amounts:³ (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2018-2020	2021	2022
Number of vaccine doses	-	369,000	355,000
Number of AD syringes	-	243,300	233,600
Number of re-constitution syringes	-	40,500	39,000
Number of safety boxes	-	3,100	3,000
Annual Amounts (US\$)	646,929	288,106	273,346

13. Procurement agency: UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

14. Self-procurement:

Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group:			Initial self-financing		
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2021	2022	2023	2024	2025
Number of vaccine doses	272,000	288,000	-	-	-
Number of AD syringes	179,500	189,800	-	-	-
Number of re-constitution syringes	30,000	31,700	-	-	-
Number of safety boxes	2,325	2,450	-	-	-
Value of vaccine doses (US\$)	178,432	207,648	-	-	-
Total co-financing payments (US\$) (including freight)	192,209	221,783	-	-	-
Minimum number of doses to be financed from domestic resources	-	-	-	-	-
Minimum amount to be financed from domestic resources (US\$)	-	-	-	-	-

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

Reports and other information :	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> ● vaccine stock levels including buffer stock, by end of March; ● number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. ● Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 15 May</p>
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable

For Gavi
Signed by



Colette Selman
Director Core Countries a.i.